migraine; rash; dry throat; earache; nausea; this is a spontaneous report received from a contactable reporter (consumer) from the regulatory agency. regulatory number: gb-mhra-webcovid-202202270008366460-rrawk. other case identifier(s): gb-mhra-adr 26656108. a 24 year-old female patient (not pregnant) received bnt162b2 (comirnaty), administration date 25feb2022 (batch/lot number: unknown) at the age of 24 years as dose 2, single for covid-19 immunisation. the patient's relevant medical history and concomitant medications were not reported. patient did not have symptoms associated with covid-19. patient was not currently breastfeeding. patient was not enrolled in clinical trial. vaccination history included: covid-19 vaccine (dose 1; manufacturer unknown), for covid-19 immunisation. the following information was reported: migraine (medically significant) with onset 26feb2022, outcome "not recovered", described as "migraine"; nausea (medically significant) with onset 25feb2022, outcome "not recovered", described as "nausea"; rash (medically significant) with onset 26feb2022, outcome "not recovered", described as "rash"; dry throat (medically significant) with onset 25feb2022, outcome "not recovered", described as "dry throat"; ear pain (medically significant) with onset 25feb2022, outcome "not recovered", described as "earache". the patient was on depo at the time of this report. the patient underwent the following laboratory tests and procedures: sars-cov-2 test: no - negative covid-19 test. patient did not test positive for covid-19 since having the vaccine. the report was not related to possible inflammation of the heart (myocarditis or pericarditis). no follow-up attempts are possible; information about lot/batch number cannot be obtained. no further information is expected